Canaccord Genuity analyst Kyle Rose maintained a Buy rating on TELA Bio (TELA) yesterday and set a price target of $18.00. The company’s shares closed last Wednesday at $16.50.
According to TipRanks.com, Rose is a 5-star analyst with an average return of 9.9% and a 53.5% success rate. Rose covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Smith & Nephew Snats, and Alphatec Holdings.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for TELA Bio with a $19.00 average price target, representing a 7.7% upside. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $20.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $23.55 and a one-year low of $5.25. Currently, TELA Bio has an average volume of 41.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TELA Bio, Inc. is a commercial stage medical technology company. It focuses on designing, developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company offers a portfolio of advanced reinforced tissue matrices that improve clinical outcomes and reduce overall costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. TELA Bio was founded by Antony Koblish and Maarten Persenaire on April 17, 2012 and is headquartered in Malvern, PA.
